2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
|Articles|October 2, 2015
- Pharmaceutical Technology-10-02-2015
- Volume 38
- Issue 10
Self-Contained Laboratory Homogenizer Prepares Injectable Drugs
GEA’s Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications.
GEA’s Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications, including nanoparticles, nanodispersions, nanoemulsions, and cell dispersions. The homogenizers can reduce particle sizes down to nanometer range for the preparation of injectable drugs.
The homogenizer is designed for continuous operation up to 1500 bar. The sanitary design is suited for clean-in-place and sterilization-in-place. The Pony NS2006L achieves the same results as larger size homogenizers, and its compact design allows easy installation with simple operation and quick maintenance. It is also suitable for viscous products.
GEA
Articles in this issue
about 11 years ago
Identifying Powder Properties that Define Process Performanceabout 11 years ago
Connecting MES to Process Controlabout 11 years ago
Parenteral Packaging Advancesabout 11 years ago
Serialization Shake Outabout 11 years ago
Investigating Biologicsabout 11 years ago
Advances in Fluorination Chemistry for API Synthesisabout 11 years ago
Small-Molecule API CMOs Are Thrivingabout 11 years ago
Modular Platform for Agitator Bead Mill Optimizes Grindingabout 11 years ago
Microfluidics Systems Designed for Flow-Chemistry ExperimentsRelated to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.